IOL Chemicals & Pharmaceuticals

IOL Chemicals & Pharmaceuticals

97.53
-0.52
(-0.53%)
hide
Key Fundamentals
Add Ratio
Market Cap
2,878.00 Cr
EPS
3.44
PE Ratio
27.23
Dividend Yield
0.82 %
Industry
Healthcare
52 Week High
126.66
52 Week Low
57.50
PB Ratio
1.70
Debt to Equity
0.05
Analyst Rating and Forecast
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Vasudeva Commercials Transfers 3.94% Stake in IOL Chemicals Following NCLT-Approved DemergerToday
Vasudeva Commercials Limited disclosed an off-market transfer of 1,15,78,195 shares (3.94% stake) in IOL Chemicals and Pharmaceuticals Limited to Synthorix Trading Limited. The transfer occurred following the National Company Law Tribunal's approval of a demerger scheme between Vasudeva Commercials (demerged company) and Synthorix Trading (resulting company). Post-transfer, Vasudeva Commercials' holding in IOL Chemicals reduced from 7.94% to 4.00%. The NCLT order was dated September 25, 2025, with formal order on October 9, 2025, and the share transfer completed on October 17, 2025. IOL Chemicals has a total equity share capital of Rs. 58,70,55,020 comprising 29,35,27,510 equity shares of Rs. 10 each.
positive
IOL Chemicals and Pharmaceuticals Limited received a Certificate of Suitability from the European Directorate for the Quality of Medicines & Health Care (EDQM) for their API product Pantoprazole Sodium Sesquihydrate Process-III on October 14, 2025. Pantoprazole sodium is a proton pump inhibitor that reduces stomach acid and is used to treat gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome.
positive
IOL Chemicals and Pharmaceuticals Limited reported quarterly revenue of Rs. 552 crores, reflecting 9.8% year-on-year growth from Rs. 502 crores in the previous year. EBITDA increased 19.5% to Rs. 69.5 crores from Rs. 58.2 crores, with margins improving 102 basis points to 12.4%. Profit after tax rose 14.4% to Rs. 34 crores. The company's newly commissioned 10,800 MTPA Paracetamol plant has begun exports to European markets and is currently operating at 34% capacity, expected to reach 60% by Q3. The company is targeting a 50-50 split between Ibuprofen and non-Ibuprofen APIs, with non-Ibuprofen currently at 34% share. Export revenue comprises 25% of total sales, with plans to increase this to 40% over two years. The company received REACH registration for Acetic Anhydride in EU markets and earned an EcoVadis Silver Medal for sustainability performance. Management maintains guidance of 14-15% EBITDA margins and 10% revenue growth for the full year.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,679.10
#1 3,98,049.70
38.75
#1 54,729.00
9.71
#1 10,980
-19.84
61.71
6,621.50
1,75,222.50
76.19
9,712.00
18.67
2,191
26.74
72.60
1,577.60
1,26,768.90
23.67
28,409.50
7.12
5,291
9.88
60.63
3,584.30
1,19,599.80
60.49
11,539.40
6.99
1,911
19.91
53.74
1,255.90
1,03,508.80
#1 18.25
33,741.20
16.73
5,725
1.26
48.97
2,476.60
1,01,344.60
53.48
12,744.20
#1 20.90
2,007
-18.14
47.04
987.65
99,073.80
21.09
23,511.00
18.55
4,615
2.60
45.37
1,940.00
89,121.90
23.79
22,909.50
13.74
3,306
#1 51.64
46.82
5,581.50
66,047.70
28.61
13,458.30
3.70
2,216
21.39
63.11
1,101.00
64,254.10
19.04
32,345.60
9.43
3,484
-10.24
50.87
Growth Rate
Revenue Growth
-2.83 %
Net Income Growth
-24.78 %
Cash Flow Change
-38.36 %
ROE
-28.18 %
ROCE
-26.58 %
EBITDA Margin (Avg.)
-11.29 %

Quarterly Financial Results

Quarterly Financials
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
579
570
547
530
596
570
552
529
511
510
532
527
532
559
Expenses
527
509
510
481
492
491
481
476
454
451
484
476
465
490
EBITDA
52
61
37
49
104
80
71
53
57
59
48
51
67
70
Operating Profit %
8 %
10 %
6 %
8 %
16 %
13 %
12 %
9 %
10 %
10 %
8 %
9 %
12 %
11 %
Depreciation
11
11
11
12
12
14
16
16
16
17
18
19
19
20
Interest
2
3
4
5
5
4
4
4
3
2
4
5
4
4
Profit Before Tax
39
47
22
33
87
61
51
32
37
40
26
28
45
46
Tax
9
12
6
9
22
15
13
9
10
10
7
7
13
12
Net Profit
30
35
16
24
65
46
38
23
28
30
19
21
31
34
EPS in ₹
5.07
5.91
2.71
4.05
11.03
7.81
6.45
3.93
4.71
5.11
3.26
3.50
1.07
1.16

Balance Sheet

Balance Sheet
2022
2023
2024
2025
Total Assets
1,962
2,022
2,244
2,382
Fixed Assets
561
752
933
1,171
Current Assets
1,081
920
1,120
1,151
Capital Work in Progress
105
90
101
22
Investments
2
20
20
21
Other Assets
1,294
1,161
1,190
1,169
Total Liabilities
1,962
2,022
2,244
2,382
Current Liabilities
513
456
560
610
Non Current Liabilities
57
58
73
85
Total Equity
1,392
1,508
1,612
1,688
Reserve & Surplus
1,334
1,449
1,553
1,629
Share Capital
59
59
59
59

Cash Flow

Cash Flow
2022
2023
2024
2025
Net Cash Flow
-29
-2
6
71
Investing Activities
-121
-120
-191
-154
Operating Activities
93
122
290
179
Financing Activities
-2
-4
-93
46

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
43.69 %
43.69 %
43.69 %
43.69 %
43.69 %
43.69 %
43.69 %
43.69 %
48.19 %
48.19 %
48.19 %
48.19 %
48.19 %
48.19 %
48.19 %
52.62 %
52.62 %
52.62 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
2.34 %
2.18 %
1.41 %
1.39 %
1.63 %
1.49 %
1.47 %
2.59 %
DIIs
0.04 %
0.04 %
0.36 %
0.50 %
0.02 %
0.02 %
0.06 %
0.17 %
0.02 %
0.26 %
0.36 %
0.37 %
0.30 %
0.10 %
0.08 %
0.08 %
0.07 %
0.02 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
27.30 %
28.03 %
29.86 %
30.15 %
30.29 %
31.15 %
31.15 %
30.92 %
30.49 %
29.28 %
30.28 %
30.63 %
30.98 %
31.48 %
31.31 %
31.23 %
31.43 %
30.22 %
Others
28.97 %
28.24 %
26.08 %
25.66 %
25.99 %
25.14 %
25.10 %
25.23 %
21.30 %
22.26 %
18.84 %
18.62 %
19.12 %
18.84 %
18.79 %
14.58 %
14.40 %
14.54 %
No of Share Holders
1,09,092
1,27,893
1,42,022
1,45,041
1,46,437
1,48,907
1,45,692
1,43,327
1,40,177
1,26,004
1,35,397
1,34,235
1,30,003
1,28,689
1,25,979
1,26,701
1,30,002
1,25,040

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 3 6 4 4 5 0.8
Dividend Yield (%) 0.00 0.00 0.00 0.00 2.72 8.48 7.07 5.53 8.18 0.82

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
12 Sept 2021 DIVIDEND Dividend
₹ 2.00 /share
08 Sept 2021 142.80 110.43
16 Feb 2022 DIVIDEND Dividend
₹ 4.00 /share
15 Feb 2022 91.71 77.42
17 Feb 2023 DIVIDEND Dividend
₹ 4.00 /share
17 Feb 2023 62.59 63.30
16 Feb 2024 DIVIDEND Dividend
₹ 5.00 /share
16 Feb 2024 87.56 82.25
23 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
23 Aug 2024 74.72 93.30
14 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Nov 2024 79.07 74.06
12 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Feb 2025 72.62 73.57
18 Feb 2025 DIVIDEND Dividend
₹ 4.00 /share
18 Feb 2025 73.57 68.18
27 Dec 2024 SPLIT Split
2:10
11 Mar 2025 82.27 82.27
16 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
16 May 2025 65.00 77.10
07 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Aug 2025 94.23 95.10
22 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
22 Aug 2025 77.10 98.25

Announcements

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 20116 hours ago
EDQM Issued CEP Certificate For Pantoprazole Sodium Sesquihydrate Process-III3 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Intimation On Receipt Of Request For Re-Lodgement Of Transfer Requests Of Physical SharesOct 01, 2025
Closure of Trading WindowSep 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 25, 2025
Dispatch Of Reminder Letter To Shareholders To Update KYCSep 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 09, 2025
Clarification On Volume MovementSep 09, 2025
Clarification sought from IOL Chemicals & Pharmaceuticals LtdSep 09, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 29, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 22, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 22, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 08, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 07, 2025
Board Meeting Outcome for Outcome Of The Board Meeting And Submission Of Un-Audited Financial Results For The Quarter Ended 30Th June 2025Aug 07, 2025
Un-Audited Financial Results For The Quarter Ended 30Th June 2025Aug 07, 2025
Intimation Pursuant To Regulation 36(1)(B) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 31, 2025
Reg. 34 (1) Annual Report.Jul 31, 2025
Notice Of 38Th Annual General Meeting (AGM) Of The CompanyJul 31, 2025
Board Meeting Intimation for Notice Of The Board MeetingJul 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 22, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 22, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 15, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJul 01, 2025
Closure of Trading WindowJun 26, 2025
REACH Registration For Acetic AnhydrideJun 13, 2025
IOL Awarded Ecovadis Silver Medal - Ranks Among The Top 15% Companies GloballyJun 11, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 20, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 17, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 17, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 16, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Dated 16Th May 2025May 16, 2025
Audited Financial Results For The Quarter And Year Ended 31St March 2025May 16, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 15, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 14, 2025
Board Meeting Intimation for Notice Of The Board MeetingMay 06, 2025
Intimation Under SEBI (LODR) Regulations 2015 - CDE China Approved IbuprofenApr 28, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 28, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Bandhan BSE Healthcare Index Fund Direct-Growth
0.09%
-46
0.01%
0.00%

Technical Indicators

RSI(14)
Neutral
40.91
ATR(14)
Less Volatile
4.21
STOCH(9,6)
Oversold
16.90
STOCH RSI(14)
Neutral
22.48
MACD(12,26)
Bearish
-1.21
ADX(14)
Weak Trend
20.81
UO(9)
Bearish
37.39
ROC(12)
Downtrend And Accelerating
-5.11
WillR(14)
Oversold
-81.15